Inhibition of glutathione S-transferase 3-3 by glutathione derivatives that bind [PMID: 1883342] Laboratory literature summary: Inhibition of glutathione S-transferase 3-3 by glutathione derivatives that bind covalently to the active site
Up to $30M / 48 Months - the most significant post-Phase II funding pathway in the program's history
Unlicensed intravenous glutathione infusions, sometimes offered through private 'wellness' clinics, carry additional risks including infection, contamination, and anaphylaxis
For example, a high dose of N-acetylcysteine (1,200 mg/day) paradoxically increased oxidative damage in hypertensive patients, while 600 mg/day reduced MDA by 27% (Szkudlinska et al., 2016)
Performance & recovery: Glutathione injection, then on noninjection days use NAC and glycine (a GlyNAC style approach) to support endogenous glutathione